Kos strengthens Cardiovascular Portfolio as Biovail Restructures
By Business Review Editor
Pharma Deals Review: Vol 2005 Issue 60 (Table of Contents)
Published: 5 Jun-2005
DOI: 10.3833/pdr.v2005.i60.675 ISSN: 1756-7874
Section: Distribution & Marketing
Fulltext:
Abstract
Kos pharmaceuticals acquired the US sales and marketing rights to the long-acting antihypertensive agent Cardizem® LA from Biovail for US$104 M...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS